Cargando…

Metabolite profile of a mouse model of Charcot–Marie–Tooth type 2D neuropathy: implications for disease mechanisms and interventions

Charcot–Marie–Tooth disease encompasses a genetically heterogeneous class of heritable polyneuropathies that result in axonal degeneration in the peripheral nervous system. Charcot–Marie–Tooth type 2D neuropathy (CMT2D) is caused by dominant mutations in glycyl tRNA synthetase (GARS). Mutations in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bais, Preeti, Beebe, Kirk, Morelli, Kathryn H., Currie, Meagan E., Norberg, Sara N., Evsikov, Alexei V., Miers, Kathy E., Seburn, Kevin L., Guergueltcheva, Velina, Kremensky, Ivo, Jordanova, Albena, Bult, Carol J., Burgess, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958279/
https://www.ncbi.nlm.nih.gov/pubmed/27288508
http://dx.doi.org/10.1242/bio.019273
_version_ 1782444287079743488
author Bais, Preeti
Beebe, Kirk
Morelli, Kathryn H.
Currie, Meagan E.
Norberg, Sara N.
Evsikov, Alexei V.
Miers, Kathy E.
Seburn, Kevin L.
Guergueltcheva, Velina
Kremensky, Ivo
Jordanova, Albena
Bult, Carol J.
Burgess, Robert W.
author_facet Bais, Preeti
Beebe, Kirk
Morelli, Kathryn H.
Currie, Meagan E.
Norberg, Sara N.
Evsikov, Alexei V.
Miers, Kathy E.
Seburn, Kevin L.
Guergueltcheva, Velina
Kremensky, Ivo
Jordanova, Albena
Bult, Carol J.
Burgess, Robert W.
author_sort Bais, Preeti
collection PubMed
description Charcot–Marie–Tooth disease encompasses a genetically heterogeneous class of heritable polyneuropathies that result in axonal degeneration in the peripheral nervous system. Charcot–Marie–Tooth type 2D neuropathy (CMT2D) is caused by dominant mutations in glycyl tRNA synthetase (GARS). Mutations in the mouse Gars gene result in a genetically and phenotypically valid animal model of CMT2D. How mutations in GARS lead to peripheral neuropathy remains controversial. To identify putative disease mechanisms, we compared metabolites isolated from the spinal cord of Gars mutant mice and their littermate controls. A profile of altered metabolites that distinguish the affected and unaffected tissue was determined. Ascorbic acid was decreased fourfold in the spinal cord of CMT2D mice, but was not altered in serum. Carnitine and its derivatives were also significantly reduced in spinal cord tissue of mutant mice, whereas glycine was elevated. Dietary supplementation with acetyl-L-carnitine improved gross motor performance of CMT2D mice, but neither acetyl-L-carnitine nor glycine supplementation altered the parameters directly assessing neuropathy. Other metabolite changes suggestive of liver and kidney dysfunction in the CMT2D mice were validated using clinical blood chemistry. These effects were not secondary to the neuromuscular phenotype, as determined by comparison with another, genetically unrelated mouse strain with similar neuromuscular dysfunction. However, these changes do not seem to be causative or consistent metabolites of CMT2D, because they were not observed in a second mouse Gars allele or in serum samples from CMT2D patients. Therefore, the metabolite ‘fingerprint’ we have identified for CMT2D improves our understanding of cellular biochemical changes associated with GARS mutations, but identification of efficacious treatment strategies and elucidation of the disease mechanism will require additional studies.
format Online
Article
Text
id pubmed-4958279
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Company of Biologists Ltd
record_format MEDLINE/PubMed
spelling pubmed-49582792016-08-04 Metabolite profile of a mouse model of Charcot–Marie–Tooth type 2D neuropathy: implications for disease mechanisms and interventions Bais, Preeti Beebe, Kirk Morelli, Kathryn H. Currie, Meagan E. Norberg, Sara N. Evsikov, Alexei V. Miers, Kathy E. Seburn, Kevin L. Guergueltcheva, Velina Kremensky, Ivo Jordanova, Albena Bult, Carol J. Burgess, Robert W. Biol Open Research Article Charcot–Marie–Tooth disease encompasses a genetically heterogeneous class of heritable polyneuropathies that result in axonal degeneration in the peripheral nervous system. Charcot–Marie–Tooth type 2D neuropathy (CMT2D) is caused by dominant mutations in glycyl tRNA synthetase (GARS). Mutations in the mouse Gars gene result in a genetically and phenotypically valid animal model of CMT2D. How mutations in GARS lead to peripheral neuropathy remains controversial. To identify putative disease mechanisms, we compared metabolites isolated from the spinal cord of Gars mutant mice and their littermate controls. A profile of altered metabolites that distinguish the affected and unaffected tissue was determined. Ascorbic acid was decreased fourfold in the spinal cord of CMT2D mice, but was not altered in serum. Carnitine and its derivatives were also significantly reduced in spinal cord tissue of mutant mice, whereas glycine was elevated. Dietary supplementation with acetyl-L-carnitine improved gross motor performance of CMT2D mice, but neither acetyl-L-carnitine nor glycine supplementation altered the parameters directly assessing neuropathy. Other metabolite changes suggestive of liver and kidney dysfunction in the CMT2D mice were validated using clinical blood chemistry. These effects were not secondary to the neuromuscular phenotype, as determined by comparison with another, genetically unrelated mouse strain with similar neuromuscular dysfunction. However, these changes do not seem to be causative or consistent metabolites of CMT2D, because they were not observed in a second mouse Gars allele or in serum samples from CMT2D patients. Therefore, the metabolite ‘fingerprint’ we have identified for CMT2D improves our understanding of cellular biochemical changes associated with GARS mutations, but identification of efficacious treatment strategies and elucidation of the disease mechanism will require additional studies. The Company of Biologists Ltd 2016-06-10 /pmc/articles/PMC4958279/ /pubmed/27288508 http://dx.doi.org/10.1242/bio.019273 Text en © 2016. Published by The Company of Biologists Ltd http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
spellingShingle Research Article
Bais, Preeti
Beebe, Kirk
Morelli, Kathryn H.
Currie, Meagan E.
Norberg, Sara N.
Evsikov, Alexei V.
Miers, Kathy E.
Seburn, Kevin L.
Guergueltcheva, Velina
Kremensky, Ivo
Jordanova, Albena
Bult, Carol J.
Burgess, Robert W.
Metabolite profile of a mouse model of Charcot–Marie–Tooth type 2D neuropathy: implications for disease mechanisms and interventions
title Metabolite profile of a mouse model of Charcot–Marie–Tooth type 2D neuropathy: implications for disease mechanisms and interventions
title_full Metabolite profile of a mouse model of Charcot–Marie–Tooth type 2D neuropathy: implications for disease mechanisms and interventions
title_fullStr Metabolite profile of a mouse model of Charcot–Marie–Tooth type 2D neuropathy: implications for disease mechanisms and interventions
title_full_unstemmed Metabolite profile of a mouse model of Charcot–Marie–Tooth type 2D neuropathy: implications for disease mechanisms and interventions
title_short Metabolite profile of a mouse model of Charcot–Marie–Tooth type 2D neuropathy: implications for disease mechanisms and interventions
title_sort metabolite profile of a mouse model of charcot–marie–tooth type 2d neuropathy: implications for disease mechanisms and interventions
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958279/
https://www.ncbi.nlm.nih.gov/pubmed/27288508
http://dx.doi.org/10.1242/bio.019273
work_keys_str_mv AT baispreeti metaboliteprofileofamousemodelofcharcotmarietoothtype2dneuropathyimplicationsfordiseasemechanismsandinterventions
AT beebekirk metaboliteprofileofamousemodelofcharcotmarietoothtype2dneuropathyimplicationsfordiseasemechanismsandinterventions
AT morellikathrynh metaboliteprofileofamousemodelofcharcotmarietoothtype2dneuropathyimplicationsfordiseasemechanismsandinterventions
AT curriemeagane metaboliteprofileofamousemodelofcharcotmarietoothtype2dneuropathyimplicationsfordiseasemechanismsandinterventions
AT norbergsaran metaboliteprofileofamousemodelofcharcotmarietoothtype2dneuropathyimplicationsfordiseasemechanismsandinterventions
AT evsikovalexeiv metaboliteprofileofamousemodelofcharcotmarietoothtype2dneuropathyimplicationsfordiseasemechanismsandinterventions
AT mierskathye metaboliteprofileofamousemodelofcharcotmarietoothtype2dneuropathyimplicationsfordiseasemechanismsandinterventions
AT seburnkevinl metaboliteprofileofamousemodelofcharcotmarietoothtype2dneuropathyimplicationsfordiseasemechanismsandinterventions
AT guergueltchevavelina metaboliteprofileofamousemodelofcharcotmarietoothtype2dneuropathyimplicationsfordiseasemechanismsandinterventions
AT kremenskyivo metaboliteprofileofamousemodelofcharcotmarietoothtype2dneuropathyimplicationsfordiseasemechanismsandinterventions
AT jordanovaalbena metaboliteprofileofamousemodelofcharcotmarietoothtype2dneuropathyimplicationsfordiseasemechanismsandinterventions
AT bultcarolj metaboliteprofileofamousemodelofcharcotmarietoothtype2dneuropathyimplicationsfordiseasemechanismsandinterventions
AT burgessrobertw metaboliteprofileofamousemodelofcharcotmarietoothtype2dneuropathyimplicationsfordiseasemechanismsandinterventions